NCT05670327

Brief Summary

The prevalence and adverse effect of diaphragm dysfunction (DD) after bilateral-lung transplant (LT) are still unclear, despite a well-known negative impact on weaning and outcome in other cohorts of critically ill and surgical patients. Objects: The primary aim is investigating the prevalence of DD, assessed using point-of-care ultrasound and defined as diaphragm thickening fraction (TFdi) \< 29%, at the first weaning trial after LT. Secondary aims are investigating the impact of DD on weaning (defined success or failure according to pre-defined criteria, neuroventilatory efficiency (EAdi or NVE), perioperative (14-day) pneumonia, ICU length of stay (LOS), in-hospital mortality, and identifying potential risk factors for DD. Moreover, we aim to study the correlation between TFdi versus EAdi/NVE and the rapid shallow breathing index (RSBI), respectively.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
43

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jun 2021

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 22, 2021

Completed
1.2 years until next milestone

First Submitted

Initial submission to the registry

August 28, 2022

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 19, 2022

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2022

Completed
1 month until next milestone

First Posted

Study publicly available on registry

January 4, 2023

Completed
Last Updated

January 4, 2023

Status Verified

December 1, 2022

Enrollment Period

1.3 years

First QC Date

August 28, 2022

Last Update Submit

December 20, 2022

Conditions

Keywords

bilateral lung transplantdiaphragmatic dysfunction

Outcome Measures

Primary Outcomes (1)

  • Diaphragmatic dysfunction at ultrasound assessment

    Prevalence of DD, assessed using point-of-care ultrasound and defined as diaphragm thickening fraction (TFdi) \< 29% at the first weaning trial after lung transplant

    through study completion, an average of 1 yea

Secondary Outcomes (3)

  • Impact of TFdi on weaning

    through study completion, an average of 1 year

  • Relevant clinical correlation (spearman correlation)

    through study completion, an average of 1 yea

  • Relation between invasive mechanical ventilation (IMV) before the first weaning trial and TFdi

    through study completion, an average of 1 yea

Study Arms (1)

Bilateral lung recipients

Adult patients undergoing bilateral LT, not requiring invasive mechanical ventilation before surgery, were eligible for inclusion in the study only when they met the predefined 'readiness-to-wean' criteria on daily screening and were therefore deemed ready to undergone a first 30-min weaning trial.

Other: Diaphragmatic ultrasound assessment

Interventions

TFdi, diaphragmatic dysplacement, NAVA assessment, respiratory paramenters

Bilateral lung recipients

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Bilateral lung transplant at the first graft.

You may qualify if:

  • Adult patients
  • bilateral LT
  • absent invasive mechanical ventilation before surgery
  • fullfilling 'readiness-to-wean' criteria on daily screening (and therefore deemed ready to undergone a first 30-min weaning trial)

You may not qualify if:

  • presence of neuromuscular blockers in the previous 12 hours
  • lack of ultrasound acoustic window
  • decline to participate
  • right hemi-diaphragmatic palsy due to surgical sacrifice of right phrenic nerve
  • duplicated patients.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Institute of Anaesthesia and Intensive Care, Padua University hospital

Padua, 35120, Italy

Location

MeSH Terms

Conditions

Muscle Weakness

Condition Hierarchy (Ancestors)

Muscular DiseasesMusculoskeletal DiseasesNeuromuscular ManifestationsNeurologic ManifestationsNervous System DiseasesPathologic ProcessesPathological Conditions, Signs and SymptomsSigns and Symptoms

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal investigator

Study Record Dates

First Submitted

August 28, 2022

First Posted

January 4, 2023

Study Start

June 22, 2021

Primary Completion

October 19, 2022

Study Completion

December 1, 2022

Last Updated

January 4, 2023

Record last verified: 2022-12

Data Sharing

IPD Sharing
Will not share

Locations